Gefitinib for advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Gefitinib for advanced non-small cell lung cancer

Published:2018-01-16 Issue:1 Volume:2018 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Sim Esther HA¹,Yang Ian A²³,Wood-Baker Richard⁴,Bowman Rayleen V³,Fong Kwun M³

Affiliation:

1. GenesisCare Radiation Oncology; 1 Medical Place Urraween Queensland Australia 4655

2. The University of Queensland; UQ Thoracic Research Centre, School of Medicine; Brisbane Australia

3. The Prince Charles Hospital; Department of Thoracic Medicine; Brisbane Australia

4. University of Tasmania; School of Medicine; Hobart Tasmania Australia 7001

Publisher

Wiley

Subject

Pharmacology (medical)

Reference151 articles.

1. Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer;Ahn;Lung Cancer,2012

2. Study of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring EGFR mutation;An;Pathology and Oncology Research,2016

3. Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy;Chen;Cancer,2007

4. A phase II randomized trial of gefitinib alone or with Tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy;Chen;Journal of Thoracic Oncology,2011

5. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations;Cheng;Journal of Clinical Oncology,2016

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures;Scientific Reports;2024-05-13

2. Tanshinone IIA reverses gefitinib resistance in EGFR‐mutant lung cancer via inhibition of SREBP1‐mediated lipogenesis;Phytotherapy Research;2024-01-28

3. Management of Gefitinib resistance in lung cancer utilizing virtual screening techniques;AIP Conference Proceedings;2024

4. Identification of a novel endocytosis‑associated gene signature for prognostic prediction in lung adenocarcinoma;Oncology Letters;2023-10-12

5. Design of gefitinib-loaded PLGA microspheres via microfluidics for lung cancer;Materials & Design;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3